10-Q quarterly report · filed Nov 4, 2026

OMNICELL, INC. (OMCL) Q3 2026 10-Q Quarterly Report

Short answer

OMNICELL, INC. (OMCL) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $308M (down 0.9% year over year) with net income of $11M.

Q3 2026 key financials · XBRL

Revenue
$308M
−0.9% YoY · −1.4% QoQ
Net income
$11M
+102.2% YoY · −54.5% QoQ
Operating margin
4.9%
Gross margin
44.8%
EPS (diluted)
$0.24
+100.0% YoY · −53.8% QoQ

Source: XBRL data from the OMNICELL, INC. (OMCL) Q3 2026 10-Q on SEC EDGAR. USD.

OMNICELL, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $307.9M, down $2.8M, or 1% YoY, with product revenue down 3% to $173.1M
  • Gross margin 45% vs 43% YoY, driven by lower service costs, partially offset by higher semiconductor costs
  • Best line: service revenue up 1% to $134.8M, led by Specialty Pharmacy Services; worst: product revenue down 3%
  • Cash $314.9M vs $196.5M at December 31, 2025; operating cash flow $155.9M for nine months
  • Outlook: tariffs, labor shortages, healthcare policy changes, and Medicaid spending reductions creating margin and demand headwinds

Risk Factors

  • No material changes to previously disclosed risk factors in the December 31, 2025 Form 10-K
  • Regulatory and compliance exposure remains a significant carried-forward risk
  • Healthcare technology competition remains a key operational risk
  • Customer concentration remains a potential market risk
  • Liquidity and debt obligations remain carried-forward financial risks

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other OMNICELL, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.